0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Vitamin D Therapy and Cardiac Function in Chronic Kidney Disease

Sanjay Rajagopalan, MD; Christopher T. Chan, MD
JAMA. 2012;307(21):2253. doi:10.1001/jama.2012.4170.
Text Size: A A A
Published online

Extract

To the Editor: In the article by Dr Thadhani and colleagues1 on the effects of paricalcitol in patients with CKD, the primary end point was change in LVMI at 48 weeks by cardiac magnetic resonance imaging, which did not significantly differ between groups. The eligibility criteria specified patients with evidence of mild to moderate left ventricular hypertrophy on echocardiography. However, the baseline LVMI reported in the study of approximately 24 g/m2.7 by cardiovascular magnetic resonance imaging would not constitute left ventricular hypertrophy using previous definitions.2,3 The absence of substantial left ventricular hypertrophy at baseline may have influenced the extent of LVMI regression with the intervention, as shown by previous studies in which the extent of left ventricular hypertrophy may influence regression.4,5 These findings must temper the authors' conclusions and should be taken into consideration in designing future trials of CKD.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

June 6, 2012
Costas Fourtounas, MD, PhD
JAMA. 2012;307(21):2253. doi:10.1001/jama.2012.4168.
June 6, 2012
Ravi Thadhani, MD, MPH; Hector Tamez, MD, MPH; Scott D. Solomon, MD
JAMA. 2012;307(21):2253. doi:10.1001/jama.2012.4176.
June 6, 2012
Eduardo Slatopolsky, MD
JAMA. 2012;307(21):2253. doi:10.1001/jama.2012.4172.
June 6, 2012
Stefan D. Anker, MD, PhD; Stephan von Haehling, MD, PhD
JAMA. 2012;307(21):2253. doi:10.1001/jama.2012.4178.
CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Jobs
brightcove.createExperiences();